Cabergoline Trial to Test Breast Cancer Prevention in Postpartum BRCA1 Carriers

By Clinical Research News Staff

November 19, 2026 | A multinational, placebo-controlled phase 2 trial will test whether cabergoline, an inexpensive, off-patent drug that suppresses lactation, can lower breast cancer risk in young women who carry BRCA1 pathogenic variants. The idea is to give the drug once these women have decided to wean.

The study is led by Christopher Maxwell, Ph.D., of the University of British Columbia and BC Children’s Hospital Research Institute. It builds on involution, the process in which breast tissue clears out and remodels itself after breastfeeding ends. BRCA1 carriers face a lifetime breast cancer risk of up to 80%, and that risk rises sharply in the postpartum period. Cabergoline blocks the hormone prolactin, which speeds up involution and helps the immune system clear binucleate epithelial cells. In BRCA1-mutant mouse models, a single dose remodeled the mammary gland and reversed local immune exhaustion, according to work published in Cancer Discovery. Separately, health records from Spain and Norway have linked the drug to a lower rate of postpartum breast cancer.

The trial will enroll 55 pregnant or lactating BRCA1 carriers at sites in Vancouver, Southampton and Spain. Participants will be randomized 2:1 to the standard cabergoline dose (four doses over two days) or a placebo. Investigators will track:

  • Blood and serum biomarkers
  • Prolactin levels at baseline and one week after treatment
  • Epithelial and fibroglandular volumes on standard-of-care imaging
  • Pre-treatment milk samples, when possible
  • Breast tissue samples taken at roughly four to six months

The best time to give the drug is still unknown, and Maxwell hopes the trial will help answer that. Today, the only primary prevention option for high-risk women is surgery to remove the breasts, fallopian tubes, and ovaries. The team plans to finish clinical studies within three years and then seek regulatory approval for cabergoline as a prevention drug in Canada, the EU and the U.K. The Gray Foundation is funding the trial, with additional support from Canadian and Spanish agencies.

For Deborah Borfitz’s full story, visit Bio-IT World.

Load more comments
comment-avatar